Anthracycline-based chemotherapy as first-line treatment in adults with malignant posttransplant lymphoproliferative disorder after solid organ transplantation

Anna L. Taylor, Kristian M. Bowles, Christopher J. Callaghan, Jenny Z. Wimperis, John W. Grant, Robert E. Marcus, J. Andrew Bradley

Research output: Contribution to journalArticlepeer-review

41 Citations (Scopus)


Recommended first-line treatment for posttransplant lymphoproliferative disorder (PTLD) is reduction in immunosuppressive therapy, irrespective of histopathological type. Second-line treatment with chemotherapy is generally reserved for tumors that fail to respond to reduced immunosuppression. In view of the similarities between monomorphic PTLD and non-Hodgkin's lymphoma in the general population, our policy is to treat monomorphic PTLD with anthracycline-based chemotherapy as first-line treatment.
Original languageEnglish
Pages (from-to)375-381
Number of pages7
Issue number3
Publication statusPublished - 15 Aug 2006


  • Adolescent
  • Adult
  • Aged
  • Anthracyclines
  • Biopsy
  • Female
  • Humans
  • Kidney Transplantation
  • Lymphoma
  • Lymphoproliferative Disorders
  • Male
  • Middle Aged
  • Survival Rate
  • Time Factors
  • Treatment Outcome

Cite this